FDA reversed earlier stance and will accept accelerated review of UniQure's gene therapy, potentially enabling first treatment option for Huntington's disease.

Intellia reported positive Phase III trial results for a genetic engineering therapeutic candidate.

New anticancer vaccine demonstrates early efficacy against neuroblastoma with potential for significant tumor reduction.

FDA advisory committee endorsed mRNA-based influenza vaccine for seniors, expanding non-COVID applications for mRNA technology.

Major oncology meeting showcased continued progress in cancer vaccine development and self-administered therapies.

Weight loss medications demonstrate applications across broader disease indications beyond metabolic disorders.

New oral acute myeloid leukemia therapy provides patients over age threshold with non-infusion dosing option.

Research pinpoints glycogen metabolism as critical pathway in hepatocellular carcinoma, opening targeted treatment possibilities.

Leading mRNA vaccine developer progresses multiple therapeutic candidates beyond COVID-19.

Promising veterinary cancer treatment drew attention from FDA leadership but faces regulatory and translational challenges for human use.

Major Indian pharma firm proposed all-cash acquisition of US-based ophthalmology company at significant premium.

Biotech company achieved largest-ever sector IPO with exceptional first-day stock performance.

Australian biotech firm secured ethics approval to proceed with Phase 2b testing of KappaMab in relapsed myeloma patients.

Precision oncology company announced positive clinical data, driving strong equity performance.

Proposed regulatory framework update anticipated to streamline gene therapy development pathways.

Absci Corporation progressed AI-driven drug discovery and development initiatives.

Regulatory approval extended Type 1 diabetes immunotherapy access to pediatric population.

Biotech firm secured substantial partnership or acquisition agreement for prostate cancer therapeutic.